TY - JOUR
TI - Survival outcomes following combination of first-line platinum-based chemotherapy with S-1 in patients with advanced gastric cancer
AU - Koumarianou, A.
AU - Ntavatzikos, A.
AU - Vallilas, C.
AU - Kampoli, K.
AU - Kakoseou, Z.
AU - Karamouzis, M.V.
JO - JMIR Cancer
PY - 2020
VL - 12
TODO - 12
SP - 1-12
PB - MDPI AG
SN - null
TODO - 10.3390/cancers12123780
TODO - antineoplastic agent;  cisplatin;  oxaliplatin;  s1;  unclassified drug, adult;  advanced cancer;  aged;  anemia;  Article;  cancer localization;  cancer research;  cancer screening;  cancer survival;  clinical article;  clinical outcome;  clinical protocol;  cohort analysis;  controlled study;  diarrhea;  drug efficacy;  drug safety;  drug tolerability;  European;  fatigue;  female;  human;  inoperable cancer;  male;  multiple cycle treatment;  nausea;  neuropathy;  neutropenia;  retrospective study;  stomach cancer;  thrombocytopenia;  vomiting
TODO - The efficacy of S-1 combined with a platinum agent in the first-line setting and in patients with advanced gastric adenocarcinoma has been previously demonstrated in randomized clinical trials. However, real-world data regarding S-1 efficacy in European patients remains limited. In the present study, we reviewed the data of a European cohort of patients with advanced gastric cancer treated with first-line therapy consisting of S-1 in combination with a platinum agent. Forty-eight patients (29 with locally advanced/inoperable and 19 with metastatic disease) were treated with S-1 plus oxaliplatin (33 patients) or S1 plus cisplatin (15 patients). The Cox regression analysis, adjusted with propensity score, indicated that the use of cisplatin as compared to oxaliplatin was associated with increased risk of death (HR 9.634, p = 0.000). Four SAEs (serious adverse events) GIII were recorded (1 fatigue, 1 neutropenia, 1 anemia, 1 diarrhea) in 3 patients. S-1 combination with a platinum agent in the first-line setting in European patients with advanced gastric cancer results to similar survival outcomes and toxicity with previously reported data from Asian populations. S-1 combination with oxaliplatin seems to be associated with superior efficacy as compared to cisplatin. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
ER -